Concerns about the external validity of the study 'prevalence of persistent symptoms after treatment for Lyme borreliosis: A prospective observational cohort study'-authors´ reply.
作者信息
van den Wijngaard Cees C, Ursinus Jeanine, Vrijmoeth Hedwig D, Knoop Hans, Wong Albert, Joosten Leo A B, Hovius Joppe W, Kullberg Bart Jan
机构信息
National Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, P.O. Box 1, Bilthoven, 3720 BA, the Netherlands.
Department of Internal Medicine, Division of Infectious Diseases and Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, P.O. Box 22660, Amsterdam, 1100 DD, the Netherlands.
出版信息
Lancet Reg Health Eur. 2022 Mar 22;15:100344. doi: 10.1016/j.lanepe.2022.100344. eCollection 2022 Apr.
Abstract
摘要
相似文献
1
Concerns about the external validity of the study 'prevalence of persistent symptoms after treatment for Lyme borreliosis: A prospective observational cohort study'-authors´ reply.
Lancet Reg Health Eur. 2022 Mar 22;15:100344. doi: 10.1016/j.lanepe.2022.100344. eCollection 2022 Apr.
2
Correction to "Concerns about the external validity of the study 'prevalence of persistent symptoms after treatment for Lyme borreliosis: A prospective observational cohort study'-authors' reply".
Lancet Reg Health Eur. 2022 Jul 22;19:100449. doi: 10.1016/j.lanepe.2022.100449. eCollection 2022 Aug.
3
Concerns about the external validity of the study 'Prevalence of persistent symptoms after treatment for Lyme borreliosis: A prospective observational cohort study'.
Lancet Reg Health Eur. 2022 Mar 22;15:100340. doi: 10.1016/j.lanepe.2022.100340. eCollection 2022 Apr.
4
Prevalence and determinants of persistent symptoms after treatment for Lyme borreliosis: study protocol for an observational, prospective cohort study (LymeProspect).
BMC Infect Dis. 2019 Apr 15;19(1):324. doi: 10.1186/s12879-019-3949-8.
5
Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study.
Lancet Reg Health Eur. 2021 May 27;6:100142. doi: 10.1016/j.lanepe.2021.100142. eCollection 2021 Jul.
6
Classical Serology Does Not Aid in the Diagnosis of Persistent Symptoms Attributed to Lyme Borreliosis: A Retrospective Cohort Study.
Life (Basel). 2023 May 6;13(5):1134. doi: 10.3390/life13051134.
7
Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study.
EBioMedicine. 2023 Dec;98:104825. doi: 10.1016/j.ebiom.2023.104825. Epub 2023 Nov 27.
8
The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in Belgium.
Arch Public Health. 2017 Aug 7;75:42. doi: 10.1186/s13690-017-0202-z. eCollection 2017.
9
Corrections to "Prevalence of persistent symptoms after treatment for lyme borreliosis: a prospective observational cohort study" [The Lancet Regional Health - Europe 6 (2021) 100142].
Lancet Reg Health Eur. 2023 Mar 15;27:100622. doi: 10.1016/j.lanepe.2023.100622. eCollection 2023 Apr.
10
Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis, treatment, persistent symptoms after documented or suspected Lyme borreliosis.
Med Mal Infect. 2019 Aug;49(5):335-346. doi: 10.1016/j.medmal.2019.05.001. Epub 2019 May 31.
引用本文的文献
1
Evaluation and 1-year follow-up of patients presenting at a Lyme borreliosis expertise centre: a prospective cohort study with validated questionnaires.
Eur J Clin Microbiol Infect Dis. 2024 May;43(5):937-946. doi: 10.1007/s10096-024-04770-6. Epub 2024 Mar 16.
本文引用的文献
1
Concerns about the external validity of the study 'Prevalence of persistent symptoms after treatment for Lyme borreliosis: A prospective observational cohort study'.
Lancet Reg Health Eur. 2022 Mar 22;15:100340. doi: 10.1016/j.lanepe.2022.100340. eCollection 2022 Apr.
2
Post-treatment Lyme borreliosis in context: Advancing the science and patient care.
Lancet Reg Health Eur. 2021 Jun 27;6:100153. doi: 10.1016/j.lanepe.2021.100153. eCollection 2021 Jul.
3
Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study.
Lancet Reg Health Eur. 2021 May 27;6:100142. doi: 10.1016/j.lanepe.2021.100142. eCollection 2021 Jul.
4
Prospective Evaluation of the Frequency and Severity of Symptoms in Lyme Disease Patients With Erythema Migrans Compared With Matched Controls at Baseline, 6 Months, and 12 Months.
Clin Infect Dis. 2020 Dec 15;71(12):3118-3124. doi: 10.1093/cid/ciz1215.
5
Comparison of Clinical Course and Treatment Outcome for Patients With Early Disseminated or Early Localized Lyme Borreliosis.
JAMA Dermatol. 2018 Sep 1;154(9):1050-1056. doi: 10.1001/jamadermatol.2018.2306.
6
Standardized Symptom Measurement of Individuals with Early Lyme Disease Over Time.
Arch Clin Neuropsychol. 2017 Mar 1;32(2):129-141. doi: 10.1093/arclin/acw098.
7
Physician reported incidence of early and late Lyme borreliosis.
Parasit Vectors. 2015 Mar 15;8:161. doi: 10.1186/s13071-015-0777-6.
8
Subjective symptoms after treatment of early Lyme disease.
Am J Med. 2010 Jan;123(1):79-86. doi: 10.1016/j.amjmed.2009.05.011.
9
The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.
Clin Infect Dis. 2006 Nov 1;43(9):1089-134. doi: 10.1086/508667. Epub 2006 Oct 2.
Zotero 插件